| Dr Paula Kaye Lapinski, MD | |
|
820 Springer Dr, Lombard, IL 60148-6413 | |
| (815) 744-8554 | |
| (815) 744-3969 |
| Full Name | Dr Paula Kaye Lapinski |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 27 Years |
| Location | 820 Springer Dr, Lombard, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1437262482 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ND0101X | Dermatology - Mohs-micrographic Surgery | 036-108932 (Illinois) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
| Pinnacle Dermatology Sc | 8628353380 | 160 |
News Archive
Picis announced today that Bayonne Medical Center, Bayonne, NJ, has successfully deployed Picis ED PulseCheck™, part of the CareSuite® family of high-acuity solutions, two months ahead of schedule. This aggressive implementation is aimed at helping clinicians in the emergency department (ED) better manage information and the process of treating over 28,000 ED patients annually.
Fewer U.S. high school students are engaging in health risk behaviors compared to their counterparts from 15 years ago, according to the 2005 National Youth Risk Behavior Survey (YRBS), released today by the Centers for Disease Control and Prevention (CDC).
Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in killing leukemia cells, particularly when used in combination with chemotherapy treatments.
MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
› Verified 4 days ago
| Entity Name | Pinnacle Dermatology Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1861930984 PECOS PAC ID: 8628353380 Enrollment ID: O20170320000738 |
News Archive
Picis announced today that Bayonne Medical Center, Bayonne, NJ, has successfully deployed Picis ED PulseCheck™, part of the CareSuite® family of high-acuity solutions, two months ahead of schedule. This aggressive implementation is aimed at helping clinicians in the emergency department (ED) better manage information and the process of treating over 28,000 ED patients annually.
Fewer U.S. high school students are engaging in health risk behaviors compared to their counterparts from 15 years ago, according to the 2005 National Youth Risk Behavior Survey (YRBS), released today by the Centers for Disease Control and Prevention (CDC).
Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in killing leukemia cells, particularly when used in combination with chemotherapy treatments.
MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Paula Kaye Lapinski, MD 820 Springer Dr, Lombard, IL 60148-6413 Ph: (815) 744-8554 | Dr Paula Kaye Lapinski, MD 820 Springer Dr, Lombard, IL 60148-6413 Ph: (815) 744-8554 |
News Archive
Picis announced today that Bayonne Medical Center, Bayonne, NJ, has successfully deployed Picis ED PulseCheck™, part of the CareSuite® family of high-acuity solutions, two months ahead of schedule. This aggressive implementation is aimed at helping clinicians in the emergency department (ED) better manage information and the process of treating over 28,000 ED patients annually.
Fewer U.S. high school students are engaging in health risk behaviors compared to their counterparts from 15 years ago, according to the 2005 National Youth Risk Behavior Survey (YRBS), released today by the Centers for Disease Control and Prevention (CDC).
Researchers at Stanford University have genetically engineered yeast so it produces hydrocodone, a semi-synthetic opioid analgesic used in the United States for relief of moderate to severe pain.
New research has confirmed that cannabinoids - the active chemicals in cannabis - are effective in killing leukemia cells, particularly when used in combination with chemotherapy treatments.
MAP Pharmaceuticals, Inc. today announced results from a clinical trial comparing the pharmacokinetics (PK) and safety of LEVADEX™ orally inhaled migraine therapy with intravenous dihydroergotamine mesylate (DHE) in smokers and non-smokers. The trial was designed to measure whether systemic absorption and exposure in smokers is greater than in non-smokers. In the trial, the systemic absorption of LEVADEX was not higher and systemic exposure to DHE was not greater in smokers than in non-smokers.
› Verified 4 days ago
Nancy C Lichon, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2340 S Highland Ave Ste 350, Lombard, IL 60148 Phone: 630-932-2099 Fax: 630-932-9815 | |
Dr. Vanessa Chao Lichon, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2340 S Highland Ave Ste 350, Lombard, IL 60148 Phone: 630-932-2099 Fax: 630-932-9815 | |
Sangeetha Venkatarajan, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 500 E 22nd St Ste D, Lombard, IL 60148 Phone: 630-426-4140 | |
Dr. Robert Vincent Kolbusz, M.D. Dermatology Medicare: Not Enrolled in Medicare Practice Location: 2500 S Highland Ave, Lombard, IL 60148 Phone: 630-964-2000 Fax: 630-964-6378 | |
Michael Kenneth Schowalter, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 820 Springer Dr, Lombard, IL 60148 Phone: 815-744-8554 Fax: 630-495-1770 | |
Dr. Michael Jude Welsch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 820 Springer Dr, Lombard, IL 60148 Phone: 815-744-8554 |